BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 16759102)

  • 1. Design and synthesis of novel sulfonamide-containing bradykinin hB2 receptor antagonists. 1. Synthesis and SAR of alpha,alpha-dimethylglycine sulfonamides.
    Fattori D; Rossi C; Fincham CI; Berettoni M; Calvani F; Catrambone F; Felicetti P; Gensini M; Terracciano R; Altamura M; Bressan A; Giuliani S; Maggi CA; Meini S; Valenti C; Quartara L
    J Med Chem; 2006 Jun; 49(12):3602-13. PubMed ID: 16759102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and synthesis of novel sulfonamide-containing bradykinin hB2 receptor antagonists. 2. Synthesis and structure-activity relationships of alpha,alpha-cycloalkylglycine sulfonamides.
    Fattori D; Rossi C; Fincham CI; Caciagli V; Catrambone F; D'Andrea P; Felicetti P; Gensini M; Marastoni E; Nannicini R; Paris M; Terracciano R; Bressan A; Giuliani S; Maggi CA; Meini S; Valenti C; Quartara L
    J Med Chem; 2007 Feb; 50(3):550-65. PubMed ID: 17266207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and synthesis of novel sulfonamide-containing bradykinin hB(2) receptor antagonists. Synthesis and structure-relationships of α,α-tetrahydropyranylglycine.
    Fincham CI; Bressan A; D'Andrea P; Ettorre A; Giuliani S; Mauro S; Meini S; Paris M; Quartara L; Rossi C; Squarcia A; Valenti C; Daniela F; Maggi CA
    Bioorg Med Chem; 2012 Mar; 20(6):2091-100. PubMed ID: 22342268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MEN16132, a novel potent and selective nonpeptide antagonist for the human bradykinin B2 receptor. In vitro pharmacology and molecular characterization.
    Cucchi P; Meini S; Bressan A; Catalani C; Bellucci F; Santicioli P; Lecci A; Faiella A; Rotondaro L; Giuliani S; Giolitti A; Quartara L; Maggi CA
    Eur J Pharmacol; 2005 Dec; 528(1-3):7-16. PubMed ID: 16324696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new class of nonpeptide bradykinin B(2) receptor ligand, incorporating a 4-aminoquinoline framework. Identification of a key pharmacophore to determine species difference and agonist/antagonist profile.
    Sawada Y; Kayakiri H; Abe Y; Mizutani T; Inamura N; Asano M; Aramori I; Hatori C; Oku T; Tanaka H
    J Med Chem; 2004 May; 47(10):2667-77. PubMed ID: 15115408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of the first non-peptide full agonists for the human bradykinin B(2) receptor incorporating 4-(2-picolyloxy)quinoline and 1-(2-picolyl)benzimidazole frameworks.
    Sawada Y; Kayakiri H; Abe Y; Mizutani T; Inamura N; Asano M; Hatori C; Aramori I; Oku T; Tanaka H
    J Med Chem; 2004 May; 47(11):2853-63. PubMed ID: 15139763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differences between peptide and nonpeptide B(2) bradykinin receptor antagonists in blocking bronchoconstriction and hypotension induced by bradykinin in anesthetized Guinea pigs.
    Tramontana M; Lecci A; Meini S; Montserrat X; Pascual J; Giuliani S; Quartara L; Maggi CA
    J Pharmacol Exp Ther; 2001 Mar; 296(3):1051-7. PubMed ID: 11181940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MEN16132, a novel potent and selective nonpeptide kinin B2 receptor antagonist: in vivo activity on bradykinin-induced bronchoconstriction and nasal mucosa microvascular leakage in anesthetized guinea pigs.
    Valenti C; Cialdai C; Giuliani S; Lecci A; Tramontana M; Meini S; Quartara L; Maggi CA
    J Pharmacol Exp Ther; 2005 Nov; 315(2):616-23. PubMed ID: 16027229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel class of orally active non-peptide bradykinin B2 receptor antagonists. 4. Discovery of novel frameworks mimicking the active conformation.
    Abe Y; Kayakiri H; Satoh S; Inoue T; Sawada Y; Inamura N; Asano M; Aramori I; Hatori C; Sawai H; Oku T; Tanaka H
    J Med Chem; 1998 Nov; 41(23):4587-98. PubMed ID: 9804698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel class of orally active non-peptide bradykinin B2 receptor antagonists. 3. Discovering bioisosteres of the imidazo[1,2-a] pyridine moiety.
    Abe Y; Kayakiri H; Satoh S; Inoue T; Sawada Y; Inamura N; Asano M; Aramori I; Hatori C; Sawai H; Oku T; Tanaka H
    J Med Chem; 1998 Oct; 41(21):4062-79. PubMed ID: 9767643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new series of highly potent non-peptide bradykinin B2 receptor antagonists incorporating the 4-heteroarylquinoline framework. Improvement of aqueous solubility and new insights into species difference.
    Sawada Y; Kayakiri H; Abe Y; Imai K; Mizutani T; Inamura N; Asano M; Aramori I; Hatori C; Katayama A; Oku T; Tanaka H
    J Med Chem; 2004 Mar; 47(7):1617-30. PubMed ID: 15027853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel class of orally active non-peptide bradykinin B2 receptor antagonists. 1. Construction of the basic framework.
    Abe Y; Kayakiri H; Satoh S; Inoue T; Sawada Y; Imai K; Inamura N; Asano M; Hatori C; Katayama A; Oku T; Tanaka H
    J Med Chem; 1998 Feb; 41(4):564-78. PubMed ID: 9484506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis, biological properties, and molecular modeling investigations of novel 3,4-diarylpyrazolines as potent and selective CB(1) cannabinoid receptor antagonists.
    Lange JH; Coolen HK; van Stuivenberg HH; Dijksman JA; Herremans AH; Ronken E; Keizer HG; Tipker K; McCreary AC; Veerman W; Wals HC; Stork B; Verveer PC; den Hartog AP; de Jong NM; Adolfs TJ; Hoogendoorn J; Kruse CG
    J Med Chem; 2004 Jan; 47(3):627-43. PubMed ID: 14736243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel class of orally active non-peptide bradykinin B2 receptor antagonists. 2. Overcoming the species difference between guinea pig and man.
    Abe Y; Kayakiri H; Satoh S; Inoue T; Sawada Y; Inamura N; Asano M; Hatori C; Sawai H; Oku T; Tanaka H
    J Med Chem; 1998 Oct; 41(21):4053-61. PubMed ID: 9767642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological characterization of the bradykinin B2 receptor antagonist MEN16132 in rat in vitro bioassays.
    Meini S; Cucchi P; Catalani C; Bellucci F; Giuliani S; Santicioli P; Maggi CA
    Eur J Pharmacol; 2009 Aug; 615(1-3):10-6. PubMed ID: 19445925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bradykinin B2 and GPR100 receptors: a paradigm for receptor signal transduction pharmacology.
    Meini S; Bellucci F; Cucchi P; Giuliani S; Quartara L; Giolitti A; Zappitelli S; Rotondaro L; Boels K; Maggi CA
    Br J Pharmacol; 2004 Dec; 143(8):938-41. PubMed ID: 15545289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radioligand binding characterization of the bradykinin B(2) receptor in the rabbit and pig ileal smooth muscle.
    Meini S; Cucchi P; Catalani C; Bellucci F; Santicioli P; Giuliani S; Maggi CA
    Eur J Pharmacol; 2010 Jun; 635(1-3):34-9. PubMed ID: 20307535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bradykinin analogs containing the 4-amino-2-benzazepin-3-one scaffold at the C-terminus.
    Ballet S; De Wachter R; Van Rompaey K; Tömböly C; Feytens D; Töth G; Quartara L; Cucchi P; Meini S; Tourwé D
    J Pept Sci; 2007 Mar; 13(3):164-70. PubMed ID: 17266049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The N-terminal of icatibant and bradykinin interact with the same Asp residues in the human B2 receptor.
    Bellucci F; Meini S; Cucchi P; Catalani C; Giuliani S; Zappitelli S; Rotondaro L; Quartara L; Giolitti A; Maggi CA
    Eur J Pharmacol; 2004 May; 491(2-3):121-5. PubMed ID: 15140628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological characterization and radioligand binding properties of a high-affinity, nonpeptide, bradykinin B1 receptor antagonist.
    Ransom RW; Harrell CM; Reiss DR; Murphy KL; Chang RS; Hess JF; Miller PJ; O'Malley SS; Hey PJ; Kunapuli P; Su DS; Markowitz MK; Wallace MA; Raab CE; Jones AN; Dean DC; Pettibone DJ; Freidinger RM; Bock MG
    Eur J Pharmacol; 2004 Sep; 499(1-2):77-84. PubMed ID: 15363953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.